Catalyst
Slingshot members are tracking this event:
Top-line results from Esperion's (ESPR) Phase 3 study 1 (1002-040) of bempedoic acid in ASCVD who are inadequately controlled with current lipid-modifying therapies, including maximally tolerated statins expected in Sept 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ESPR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 25, 2018
Occurred Source:
http://investor.esperion.com/news-releases/news-release-details/esperion-announces-late-breaking-oral-presentation-final-results
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Study, Bempedoic Acid
